JCAR024 / BMS - LARVOL DELTA

LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors (AACR 2022) - "In preclinical studies LYL797 cells reprogrammed with Gen-R and Epi-R led to improved functional activity in the presence of ROR1+ tumor cells compared to conventional ROR1 CAR T cells.Additional studies are underway to determine the mechanisms by which antitumor activity of LYL797 in ROR1-positive solid tumor xenograft models is enhanced. LYL797 is anticipated to enter into Phase 1 clinical trials for TNBC and NSCLC in 2022."

CAR T-Cell Therapy • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer • JUN • ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1 | N=21 | Terminated | Sponsor: Fred Hutchinson Cancer Research Center | N=60 ➔ 21 | Trial completion date: Dec 2023 ➔ Sep 2021 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2022 ➔ May 2021; Terminated due to slow accruals.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

"And again. $BMY Ror1 Car-T, presumably JCAR024, in today's investor deck $ONCT $MRK" (@JacobPlieth)

ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Trial completion date: Dec 2037 ➔ Dec 2023

Clinical • Trial completion date • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

"How about that. $BMY lists ROR1 Car-T (=JCAR024?) in its pipeline. $ONCT $MRK" (@JacobPlieth)

ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Trial completion date: Dec 2036 ➔ Dec 2037; Trial primary completion date: Dec 2021 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Phase classification: P1/2 ➔ P1

Clinical • Phase classification • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1; N=60; Enrolling by invitation; Sponsor: Fred Hutchinson Cancer Research Center; Not yet recruiting ➔ Enrolling by invitation

Clinical • Enrollment open • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1/2; N=60; Not yet recruiting; Sponsor: Fred Hutchinson Cancer Research Center

Clinical • New P1 trial • New P1/2 trial • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Suspended ➔ Recruiting

Clinical • Enrollment open • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Thoracic Cancer • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Enrolling by invitation ➔ Recruiting

Clinical • Enrollment status • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov) - P1; N=60; Suspended; Sponsor: Fred Hutchinson Cancer Research Center; Recruiting ➔ Suspended

Clinical • Trial suspension • Acute Lymphocytic Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Mantle Cell Lymphoma • Non Small Cell Lung Cancer • Oncology • T Acute Lymphoblastic Leukemia • Thoracic Cancer • Triple Negative Breast Cancer • ALK • ER • HER-2 • PGR • ROR1

"What now for JCAR024? Over to $BMY #ASH20" (@JacobPlieth)

[VIRTUAL] Engineered variants of Neo-2/15 potently expand CAR-T cells and promote antitumor activity in lymphoma and solid tumor mouse models (AACR-II 2020) - "In a B cell tumor xenograft model, targeted Neo-2/15 effectively increased CAR-T cell expansion and prolonged survival compared to treatment with CAR-T cells and non-targeted Neo-2/15. Together, these results show that engineered versions of Neo-2/15 induce robust expansion of CAR-T cells and can enhance their antitumor activity."

CAR T-Cell Therapy • IO Biomarker • Preclinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • CD8 • IL15 • IL2 • KRAS

"@DrPaulyDeSantis @dan_smithey $JUNO catalysts updated" - dough, @tgtxdough

Anticipated P1 data • Anticipated P1/2 data • Tweet • Hematological Malignancies • Oncology